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ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a major  cause 
of high mortality and morbidity  worldwide. Symptoms of  the 
disease are usually related with the results of pulmonary dynamic 
hyperinflation. Treatment options are classified as invasive-
noninvasive and mostly tend to be  palliative. Lung volume 
reduction techniques are invasive part of the treatment and can 
be performed by  surgical or bronchoscophic  methods. Because 
of the low complication rates bronchoscophic methods became 
more popular in recent years.  Patients presenting with severe air 
trapping and thoracic hyperinflation have the greatest potential 
to derive benefit from volume reduction procedures. Assessment 
of patients should ideally include cardiological evaluation, high 
resolution CT scan, ventilation and perfusion scintigraphy, full 
pulmonary function tests, and cardiopulmonary exercise testing.
There are three main groups of bronchoscophic volume 
reduction, direct effect on lung parenchyma, airway bypass 
and blocking the airways. Indications and contraindications 
are different for each modality and device. Patients who have 
deterioration despite  habitual changes and medical therapies 
should be evaluated for volume reduction procedures.
Keywords: COPD, Emphysema, Hyperinflation, Lung volume 
reduction, Bronchoscopic
Introduction
Chronic obstructive pulmonary disease (COPD) causes 
high  mortality and morbidity worldwide.  It is estimated 
that 65 million people suffer from COPD and it is expected 
that disease will be third most common cause of death in 
2020 [1]. It will also be the fifth cause of Disability Adjusted 
Life Years (DALY) lost by the year 2020  [2].
Symptoms of the disease such as shortness of the 
breath and reduced exercise capacity are usually results of 
irreversible bronchial constriction and dynamic pulmonary 
hyperinflation [3]. Emphysema form of disease is 
characterized by abnormal and permanent enlargement of 
the airspaces and usually results in reduced transpulmonary 
recoil pressures and chest wall mechanics. These changes 
lead to hypercapnia and hypoxia that often require oxygen 
support  [4].  Risk factors for COPD are known as smoking, 
biomass exposure to organic and inorganic chemical agents, 
poor socioeconomic status, bronchial asthma, bronchial 
hypersensitivity, chronic bronchitis, early childhood 
infections, and tuberculosis [5]. 
Treatment options for  COPD
Treatment options for COPD  (invasive and noninvasive) tend 
to be palliative rather than curative. Noninvasive treatment 
options are cessation of tobacco, prophylactic vaccination 
against to pneumococci and influenza, respiratory therapy 
and medical therapy that contains anticholinergics, 
β2 sympathomimetics, inhaled glucocorticosteroids, 
phosphodiesterase inhibitors mucolytics, antioxidants and 
nutritive support to protect from muscle atrophy. Patients 
with chronic hypoxemic respiratory insufficiency may also 
utilize long term oxygen therapy and noninvasive mechanical 
ventilation. Management of the medical therapy depends 
on evidence based ‘Global Initiative for Management of 
Obstructive Lung Diseases’ (GOLD) that classify severity of 
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the diseases according to post-bronchodilator FEV1 values 
[5]. According to GOLD guideline cessation of tobacco is 
single intervention that modifies lung function and increases 
survival [5].  Despite these therapies most of the patients 
with moderate to severe illness have minimal or no control 
on disease or deteriorate rapidly that make them a candidate 
for lung transplantation or for other invasive procedures  [6]. 
Surgical management of emphysema was first described 
in 1954 as removal of the hyperinflated and physiologically 
nonfunctional parts of the lung [7].  Because of postoperative 
persistent air leaks and high mortality rates operation did not 
become popular until end of 1990s. In 2003, ‘The National 
Emphysema Treatment Trial’ reported the post operative high 
mortality (7.9% within 90 days)  in surgery group, however 
they showed improvement in exercise capacity and quality 
of life with predominantly upper lobe emphysema [8].  But 
still because of high mortality,  restriction of patient selection 
criteria, cost and effectiveness, medical communities did not 
approve surgical lung volume reduction (LVR). Because of 
these disadvantages brochoscophic lung volume reduction 
(BVR) developed in recent years. 
The principle of BVR is the same as LVR surgery with 
low complication rates [9]. According to their mechanism 
there are three main groups of BVR techniques: methods 
that have direct effect on lung parenchyma (polymeric 
lung volume reduction, coils and thermal vapor ablation), 
methods that facilitate the expiration of trapped air from the 
emphysematous lung (airway bypass) and methods employing 
devices that block the airways (spigots and unidirectional 
valves) [10]. Patients with diagnosis of hyperinflation in 
chest X Ray or pulmonary computed tomography  (CT), 
forced expiratory volume in one seconds (FEV1) values less 
than 500mL, arterial partial oxygen pressure (PaO2) less 
than 50 mmHg and arterial carbon dioxide partial pressure 
(PaCO2) more than 50 mmHg are candidates for BLVR 
procedure. Patients should quit  smoking and must enroll 
in a pulmonary physiotherapy program [11]. Comparing 
with LVR, this procedure can be performed under sedation, 
general anesthesia is not obligatory. 
Recently,  completed multicenter studies show that not 
all classes and phenotypes of emphysema benefit from 
BVR, and that each technique appears to provide a greater 
benefit to specific subgroup of patients, because of the high 
cost of the procedures selections must be done carefully. The 
initial screening for suitable candidates should be performed 
at the pulmonologist level on patients with stable disease 
and no recent exacerbations. 
The evaluation should include a through history 
(level of dyspnea, functional impairment, past thoracic 
surgery, comorbidities and smoking status) and physical 
examination. Thorax CT especially HRCT is essential to see 
the heterogeneity, fissure integrity, degree of destruction and 
ruling out underlying diseases such as lung cancer. Other 
tests are pulmonary function tests (full parameters including 
RV, TLC, DLCO), 6-minute walking test (6MWT), arterial 
blood gases, echocardiography should be completed before 
finalizing BVR decision. BVR should not be offered to active 
smokers, patients with pulmonary hypertension, unstable 
cardiac pathology, active respiratory infections or a very 
poor exercise tolerance, patients with no clear evidence of 
hyperinflation or patients who are on any type of antiplatelet 
or anticoagulant therapy which cannot be stopped for 7 days 
prior to the procedure [12].   
Indications
• 40-75 years
• Heterogeneous emphysema and no collateral 
ventilation (valves)
• Dyspnea (Despite maximal medical therapy and 
pulmonary rehabilitation)
• FEV1 15-45%
• Hyperinflation with TLC >100% and RV > 150-
175%
• PaCO2 < 50mmHg
• PaO2> 45mmHg (while breathing ambient air)
• 6MWD > 140m 
Contraindications
• Homogeneous emphysema  (valves)
• Collateral ventilation /non-intact fissures
• >75% parenchymal destruction on HRCT (coils)
• Current smoking  (at least quit 6 months)
• DLCO <20%
• Giant bullae (>1/3 of hemithorax)
• Alfa-1 Antitrypsin deficiency
• Previous thoracotomy, pleurodesis
• Chest wall deformity
• Excessive sputum
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• Severe pulmonary Hypertension (>50mmHg)
• Active infection
• unstable cardiac conditions
• Significant pleural or interstitial changes on HRCT
• Any type of platelet or anticoagulant therapy which 
cannot be stopped for 7 days prior to the procedure
Modalities and Devices
Unidirectional Endobronchial and Intrabronchial Valves
unidirectional endobronchial valves are certainly the most 
widely studied devices for the bronchoscopic treatment of 
emphysema also have the largest series of treated patients.
There are two different types of valves available on 
the market zephyr valves (Pulmonx, Inc., CA, uSA) and 
IBV (Spiration Inc., Washington, uSA). These devices are 
self-expanding and delivered with a working channel of a 
flexible bronchoscope. 
zephyr valves are made of nitinol (nickel titanium) 
mesh covered by silicone and contains double silicone 
membrane inside that opens during expiration and closes 
during inspiration [10].  zephyr valves are available in two 
sizes, one for segmental (4.0-9.0 mm) and one for lobar 
bronchi (5.5-8.5 mm), anchorage of the valve to the airway 
is facilitated by the irregular surface and self-expanding 
strength of the mesh.
Intrabronchial valves are umbrella-shaped devices made 
of a nitinol mesh covered by a polyurethane membrane 
[10]. The valve is secured to the airway wall by hook-like 
anchors. It has 4 different sizes (5,6,7 and 9 mm), airways 
are sized with a balloon prior to deployment of valves with 
the aid of a flexible bronchoscope. 
Endobronchial (EBV) and intrabronchial valves are 
the most extensively studied devices for BVR. Initial 
studies showed improvement on lung function and exercise 
tolerance and also safety of procedure. Endobronchial 
Valve for Emphysema palliation Trial (VENT) was a large 
randomized multicenter study that totally 492 patients were 
enrolled. The patients were randomized to valve treatment 
arm (unilateral volume reduction) and standard medical 
care [13].  Six months later improvement on FEV1 and 
6MWT were detected in EBV group. High heterogeneity 
emphysema and intact fissures were related with high 
success rates but complications after EBV procedure were 
significantly higher than medical treatment arm. Recently 
Ninane et al. published a European multicenter study to asses 
safety and effectiveness of bronchial valves  [14]. Results 
showed that procedure and devices were well tolerated but 
treatment without complete lobar occlusion in both upper 
lobes was ineffective in most of the patients. After this study 
Eberhardt et al. confirmed that unilateral intrabronchial 
valve placement with complete occlusion is superior to 
bilateral partial occlusion [15]. Finally STELVIO study 
showed that the lack of collateral ventilation is essential for 
the success of BVR with valves [16]. 
Coils  
Nitinol spring-like coils in a straightened configuration 
are passed through the working channel of a flexible 
bronchoscope into subsegmental airways (PneumRx). 
When deployed, coil up and tether the lung. They have 
been designed for patients with either homogeneous or 
heterogeneous emphysema.  It is available in 3 lengths (100, 
125, 150mm) and implanted via a flexible bronchoscope 
under general anaesthesia or conscious sedation with a 
delivery system under fluoroscopic guidance. The airway 
in the selected segment is identified with a low –stiffness 
guidewire (under fluoroscopy), after which a catheter 
is passed over the guidewire and length of the airway is 
measured. After removing guidewire a straightened coil is 
introduced into the distal end of catheter with a grasper, 
after which the catheter is removed while the proximal end 
of the coil is initially advanced and then released, assuming 
its performed shape12. The coils are purposed to work 
independently of collateral ventilation. The major adverse 
events are mild hemoptysis, chest pain, COPD exacerbation 
and usually occur in the first month of the procedure [17]. 
A pilot study by Herth et al. found BVR with coils to 
be safe and feasible [17].  In a multicenter study by Shah 
et al.,  47 patients with homogeneous or heterogeneous 
severe emphysema were randomized for coil treatment or 
best medical care and primary endpoint was the difference 
in response on the St. George’s Respiratory Questionnaire 
(SGRQ) between the treatment and usual care group at 90 
days later [18]. The SGQR response at 90 days after final 
treatment was greater than in the usual care group and > 
60% of the patients in BVR group experienced improvement 
in FEV1 and no significant adverse event was reported. It is 
also confirmed that BVR using coils are safe and with no 
late pneumothoraces, coil migration or unexpected adverse 
events by Hartman et al. [19]. According to this study, 3 
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years after treatment 50% of the patients maintained an 
improvement 6MWT, SGRQ and dyspnea scores. 
Current evidence would therefore suggest that both 
appropriate candidates with heterogeneous and those with 
homogeneous emphysema could experience clinically 
significant benefits from BVR using coils, irrespective of 
collateral ventilation or complete lobar collapse. 
Bronchial Plugs/Spigots
Watanable Spigots (Novatech) is a treatment option for 
persistent pneumothorax, pulmonary fistula and continuous 
air leakage [12].  There are three different sizes of plugs and 
made from silicon in conical shape. Reports about persistent 
air leakage are successful but evidence for BVR are limited. 
Toma et al., reported improvement in quality of life and 
exercise capacity after treatment in a small group, they 
also reported pneumonia as a complication due to failure of 
cleaning secretions  [12]. 
Sealants
These products (hydrogel) are developed to obtain 
atelectasis and fibrosis of the lung parenchyma [10]. 
Biological substances have now replaced by synthetic 
polymeric foam (Aeris therapeutics), the foam flows into 
the peripheral airways and acts as a glue that seals the 
target regions with consequent atelectasis [10].  It blocks 
inter-alveolar as well as bronchiolar-alveolar collaterals, 
thus it will negate the effect of collateral ventilation. This 
procedure is irreversible and common side effects are COPD 
exacerbation, self-limiting systemic inflammatory response 
with infiltrates on chest X-Ray. Recently a multicenter study 
to evaluate effectiveness of polymeric foam was terminated 
early because of severe adverse events (up to 44%of 
patients) resulting with death despite confirmed significant 
improvements in lung function, dyspnea and lung function 
tests [20].  
Airway Bypass Stents
This technique entails creation of an airway bypass passage 
between hyper-inflated lung tissue and bronchus such that 
the over inflated lobe will empty via bypass, with decrease 
in residual volume RV and air trapping [21].  First step of 
the procedure is to detect an area free of blood vessels by 
using a Doppler ultrasound, second step is fenestration 
of the airway and dilatation by a needle and final step is 
deploying a paclitaxel-coated stent to keep the passage 
open [22]. Current evidence suggest that although some 
short-term benefit may be achieved in patients with severe 
hyperinflation, the trends is for pulmonary functions to 
return to baseline overtime [21]. 
Thermal Vapor Ablation 
Bronchoscopic thermal vapor ablation (Inter Vapor uptake 
Medical) uses high-temperature vapor delivered into the 
target lung segments through a catheter with precise amount 
of energy thereby inducing thermal damage and inflammatory 
reaction resulting in permanent airway fibrosis  [10].  This 
technique is also irreversible and not limited by collateral 
ventilation. Data is limited for vapor ablation technique 
but recently two studies published improvement in clinical 
outcomes [12]. Major frequent adverse events reported as 
COPD exacerbation and pneumonia. 
Current evidence suggest that in well-defined sub-groups 
of patients with severe emphysema BVR may be of benefit. 
A well-structured approach to BVR , including initial 
screening and subsequent referral to specialized center is 
important to ensure against inappropriate use of devices, 
which may be both wasteful and harmful.
Patients with a high degree of hyperinflation and 
relatively preserved lung parenchyma are more likely to 
benefit from BVR using bilateral coils (irrespective of 
the collateral circulation and heterogeneity of the disease) 
whereas patients with heterogeneous disease, no collateral 
circulation and low baseline perfusion may benefit from 
unilateral BVR using valves with the goal of achieving 
lobar collapse. The exact utility of BVR with valves and/
or coils in homogeneous disease or the use of other devices, 
particularly sealants is still being investigated [12]. 
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